Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery
- 24 September 2012
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 110 (3) , 381-388
Abstract
We investigate the variance in patterns of failure after Gamma Knife™ radiosurgery (GKRS) for patients with brain metastases based on the subtype of the primary breast cancer. Between 2000 and 2010, 154 breast cancer patients were treated with GKRS for brain metastases. Tumor subtypes were approximated based on hormone receptor (HR) and HER2 status of the primary cancer: Luminal A/B (HR+/HER2(−)); HER2 (HER2+/HR(−)); Luminal HER2 (HR+/HER2+), Basal (HR(−)/HER2(−)), and then based on HER2 status alone. The median follow-up period was 54 months. Kaplan–Meier method was used to estimate survival times. Multivariable analysis was performed using Cox regression models. Median number of lesions treated was two (range 1–15) with a median dose of 20 Gy (range 9–24 Gy). Median overall survival (OS) was 7, 9, 11 and 22 months for Basal, Luminal A/B, HER2, and Luminal HER2, respectively (p = 0.001), and was 17 and 8 months for HER2+ and HER(−) patients, respectively (p < 0.001). Breast cancer subtype did not predict time to local failure (p = 0.554), but did predict distant brain failure rate (76, 47, 47, 36 % at 1 year for Basal, Luminal A/B, HER2, and Luminal HER2 respectively, p < 0.001). An increased proportion of HER2+ patients experienced neurologic death (46 vs 31 %, p = 0.066). Multivariate analysis revealed that HER2+ patients (p = 0.007) independently predicted for improved survival. Women with basal subtype have high rates of distant brain failure and worsened survival. Our data suggest that differences in biologic behavior of brain metastasis occur across breast cancer subtypes.Keywords
This publication has 28 references indexed in Scilit:
- The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgeryJournal of Neurosurgery, 2012
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patientsBritish Journal of Cancer, 2009
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Memory Function Before and After Whole Brain Radiotherapy in Patients With and Without Brain MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesJAMA, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatmentEuropean Journal of Cancer, 2004
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000